Wuxi Biologics Ireland Limited

Jieying Liu

Jing Li

Zhuozhi Wang

Jianqing Xu

Qin Mei

The present disclosure provides anti-CD19 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Anti-CD19 antibodies

A bispecific anti-CD3&#xd7;CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3&#xd7;CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3&#xd7;CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3&#xd7;CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3&#xd7;CD19 polypeptide complex are provided.

Bispecific CD3/CD19 polypeptide complexes

The present disclosure provides monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), which can block the binding of PCSK9 to low-density lipoprotein (LDL) receptor, and therefore lower the level low-density lipoprotein cholesterol (LDL-C). The antibodies of disclosure provide very potent agents for the treatment of multiple Cardiovascular diseases (CVDs).

Growing community of inventors

Shanghai, China

Jieying Liu